A repurposed drug that stops heart failure
The SignaCor Health drug has a known safety profile because it has been tested and approved for other conditions. It only needs to be given for approximately 8 weeks and is fast acting and effective at relieving the symptoms of heart failure.
SignaCor Health is a research group in Queen’s University Belfast working on a new treatment for heart failure. This treatment stops the development of heart stiffness and enlargement, allowing the heart to pump more effectively. This is expected to relieve patients of the symptoms of heart failure affording better quality of life and longer life expectancies.
Current treatments
Current heart failure treatments only treat the symptoms not the underlying problem and are mainly prescribed for long term use.
Only treat symptoms
Long-term use
Don't treat underlying problem
SignaCor Health Solution
Our drug stops heart stiffness and enlargement developing so relieves symptoms by halting the underlying condition. This means it extends life expectancies and improves quality of life for heart failure patients. In addition, it is only given for 8 weeks every year, reducing clinic visits. This gives patients more time to live normal and enjoy relatively clinic-free lives as well as reducing clinical care costs whilst maintaining high levels of patient care.
Our Partners & Funders
Survey
Help us shape our heart failure treatment. We need your help!
Register your interest.
Get in touch with our team today to register your interest and learn more about SignaCor Health innovative research.
©2023 SignaCor Health | Queen's University Belfast. All rights reserved.
Privacy Policy